Last reviewed · How we verify
Pioglitazone - TZD
Pioglitazone - TZD is a Thiazolidinedione (TZD) Small molecule drug developed by Royal Devon and Exeter NHS Foundation Trust. It is currently FDA-approved for Type 2 diabetes mellitus. Also known as: Actos.
Pioglitazone activates peroxisome proliferator-activated receptor gamma (PPAR-γ) to improve insulin sensitivity and reduce blood glucose in type 2 diabetes.
Pioglitazone activates peroxisome proliferator-activated receptor gamma (PPAR-γ) to improve insulin sensitivity and reduce blood glucose in type 2 diabetes. Used for Type 2 diabetes mellitus.
At a glance
| Generic name | Pioglitazone - TZD |
|---|---|
| Also known as | Actos |
| Sponsor | Royal Devon and Exeter NHS Foundation Trust |
| Drug class | Thiazolidinedione (TZD) |
| Target | PPAR-γ (Peroxisome proliferator-activated receptor gamma) |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | FDA-approved |
Mechanism of action
As a thiazolidinedione, pioglitazone binds to PPAR-γ in adipose tissue and muscle, enhancing insulin signaling and glucose uptake. This reduces hepatic glucose production and improves peripheral insulin sensitivity, leading to lower blood glucose levels without directly stimulating insulin secretion.
Approved indications
- Type 2 diabetes mellitus
Common side effects
- Weight gain
- Fluid retention and edema
- Hypoglycemia (when combined with other agents)
- Headache
- Upper respiratory tract infection
Key clinical trials
- Quantifying Hepatic Mitochondrial Fluxes in Humans (PHASE4)
- A Phase IV Clinical Trial to Compare the Efficacy and Safety of Metformin+Sodium-Glucose Cotransporter 2 Inhibitor(SGLT2-i)+Thiazolidinedione (TZD) in Patients With Type 2 Diabetes (PHASE4)
- A Study for Comparison of Canagliflozin Versus Alternative Antihyperglycemic Treatments on Risk of Heart Failure Hospitalization and Amputation for Participants With Type 2 Diabetes Mellitus and the Subpopulation With Established Cardiovascular Disease
- Changing the Natural History of Type 2 Diabetes ("CHANGE" Study) (NA)
- Antidiabetic Drugs for Steatotic Liver Disease (PHASE4)
- Quadruple Oral Combination Therapy for Type 2 Diabetes Mellitus : Glycemic Control by Thiazolidinedione (TZD) or Sodium Glucose Co-transporter 2 (SGLT-2) Inhibitor as an add-on Therapy in Type 2 Diabetes Mellitus After Failure of an Oral Triple Antidiabetic Regimen (PHASE4)
- TriMaster: Study of a DPP4 Inhibitor, SGLT2 Inhibitor and Thiazolidinedione as Third Line Therapy in Patients With Type 2 Diabetes. (PHASE4)
- HIV Acquired Lipodystrophy (HAL) Classification, Measurement and Fat Response to Thiazolidinedione (TZD) (Pioglitazone) (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Pioglitazone - TZD CI brief — competitive landscape report
- Pioglitazone - TZD updates RSS · CI watch RSS
- Royal Devon and Exeter NHS Foundation Trust portfolio CI
Frequently asked questions about Pioglitazone - TZD
What is Pioglitazone - TZD?
How does Pioglitazone - TZD work?
What is Pioglitazone - TZD used for?
Who makes Pioglitazone - TZD?
Is Pioglitazone - TZD also known as anything else?
What drug class is Pioglitazone - TZD in?
What development phase is Pioglitazone - TZD in?
What are the side effects of Pioglitazone - TZD?
What does Pioglitazone - TZD target?
Related
- Drug class: All Thiazolidinedione (TZD) drugs
- Target: All drugs targeting PPAR-γ (Peroxisome proliferator-activated receptor gamma)
- Manufacturer: Royal Devon and Exeter NHS Foundation Trust — full pipeline
- Therapeutic area: All drugs in Diabetes
- Indication: Drugs for Type 2 diabetes mellitus
- Also known as: Actos
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing